Advanced Prenatal Therapeutics, Inc. (APT)

APT is developing Breakthrough Targeted Apheresis Absorbers to filter elevated pathogenic factors in blood to safely treat leading causes of mortality WW.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Laguna Hills, CA, USA
  • Currency USD
  • Founded September 2012
  • Employees 4
  • Incorporation Type C-corp
  • Website advancedprenatal.com

Company Summary

APT has developed a breakthrough medical device platform using targeted apheresis columns that specifically and safely filter out elevated pathogenic factors from blood (in a process similar to dialysis) to treat unmet needs and the leading causes of death worldwide, including preeclampsia, myocardial infarction, cardiogenic shock, stroke, covid-19 (or the next pandemic), and other inflammatory diseases (i.e. Crohn's / IBS).

Team

  • James Smith, Ph.D.
    President / CEO

    Dr. Smith has 25 years of experience in regulatory affairs and development of novel technologies from concept through commercialization. He is experienced in all aspects of regulatory affairs, quality and data management systems, supervision of R&D, development of new product specifications, and with evaluating and registering medical drug and device product lines. Ph.D. in Pharmacology and Toxicology from University of California, Irvine.

  • Henry Smith, Ph.D.
    Chairman of the Board

    Dr. Smith has over 45 years of experience in the healthcare industry. Co-founder of several biotechnology companies and medical laboratories including NanoSmart Pharmaceuticals, Epinex Diagnostics, Allied Biotechnology International, and Associated Reference Laboratories. Senior management in medical reference laboratories including Specialty Labs and BioScience Laboratories. Ph.D. Immunology from University of Leeds Medical School, England.

  • VP Business Development

    Mr. Thiel has over 20 years experience in management positions in the biotechnology industry providing services in business development, fund raising, investor relations, marketing and PR for early-stage development companies. Mr. Thiel received his B.S. in Business from Miami University, Ohio, with a concentration in international business at Universidad de Las Americas, in Puebla, Mexico.

  • Jacqueline Morales
    VP Operations

    Ms. Morales has over 15 years experience in biotech sector supporting new product development. She has expertise in designing, auditing, and implementing ISO quality systems, preparing domestic and international regulatory filings, managing clinical laboratory operations, and overseeing marketing and corporate communications projects. Certificate in Medical Product Development, BS in Biological Sciences, minor Business Management from UC Irvine.

Advisors

Previous Investors

  • Founders
    Unconfirmed
    Private Accredited Investors
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free